Bluechiip Limited (ASX:BCT) a leader in the development of sample-tracking technology for harsh environments, today announced the signing of a three-year $US11.6 million ($A15.9 million) deal to supply its chips and associated hardware and services to vial manufacturer Labcon North America.
Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).
The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.
The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.
The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.
Further information is available at http://www.bluechiip.com
Bluechiip Ltd (ASX:BCT) provides the Company's 2017-18 Highlights.
Bluechiip Limited (ASX:BCT) today released its quarterly cash flow report for the period ended 30 June 2018.
Bluechiip Ltd (ASX:BCT) provides the record of Open Briefing interview with Managing Director, Andrew McLellan on Bluechiip deliveries, recent trade show and market update.
Andrew McLellan, Bluechiip Limited (ASX:BCT) Managing Director, was recently interviewed as part of the CommSec Executive Series. In the interview Andrew McLellan explains the Company's technology, progress with Original Equipment Manufacturers and other recent initiatives.
Bluechiip Limited (ASX:BCT) advises that as of Monday, 17 July 2017, the Company has changed its provider for shareholder registry services from BoardRoom Pty Limited to Automic Registry Services.
Bluechiip Ltd (ASX:BCT), a leader in the development of sample tracking technology for harsh environments, today announced that its pro rata 1-for-3 nonrenounceable rights issue at an issue price of $0.028 per ordinary share and its associated Top-Up Facility to raise up to $2.53 million successfully closed on 30 June 2017.
Bluechiip Limited (ASX:BCT), a leader in the development of sample tracking technology for harsh environments, is pleased to provide this company update.
Bluechiip Ltd (ASX:BCT) confirms that the Offer Document, together with personalised entitlement and acceptance form, for the non-renounceable rights issue announced by the Company on 1 June 2017, was sent to all eligible shareholders.
Bluechiip Limited (ASX:BCT) announced to the ASX a non-renounceable rights issue at an issue price of $0.028 per new share.